Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Core Points - Precision BioSciences held a business update call for AASLD 2025, featuring key executives including the CEO, CFO, and Chief Scientific Officer [1][2] - The call included a presentation format where speakers referenced specific slides for detailed information [2] Company Overview - The company is focused on advancements in the field of hepatic and infectious diseases, as indicated by the involvement of Dr. Mark Sulkowski, a renowned expert in these areas [1] - The leadership team consists of experienced professionals, highlighting the company's commitment to strong governance and expertise in its operations [1]